No Data
JMP Securities Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
Promising Developments and Strategic Advancements Support Buy Rating for Solid Biosciences
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Solid Biosciences' Innovative Gene Therapy SGT-212 Gains Buy Rating Amid Promising Preclinical Results and FDA Approval
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
12 Health Care Stocks Moving In Friday's Pre-Market Session